Biomarkers Market by Type (Safety Biomarker, Efficacy Biomarker, Validation Biomarker, and Others), Product (Consumables, Services, and Software), Application (Diagnostics, Drug Discovery & Development, Personalized Medicines, and Others), Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, and Others): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026788 | Pages: 100 | Industry: Biotechnology | Date: Oct 2022 | Type: Global

The market crossed US$ 35.72 million mark in 2022 and is expected to hit US$ 87.59 million by 2030, recording a CAGR of 11.9% during the forecast period.

The Quintessential Factors of Biomarkers

According to the National Health Council report, a chronic disease lasts for three months or longer, affecting 40 million Americans that are limited in their usual activity owing to one or more chronic health conditions. For example, chronic disease affects about half of all adults suffering from chronic conditions, affecting approximately 8% of children aged 5 to 17 years. There is no easy solution for the rising chronic diseases, but the emerging field of biomarkers acts lucrative opportunity for clinicians. For example, one of the driving forces of lipidomics research is utilizing biological samples such as faeces to determine metabolites in healthy people. In such cases, health biomarkers could hold the potential key for developing pharmaceutical interventions for treating and perhaps preventing diseases such as diabetes.

Biomarker based diagnostics in move to help cancer patients

According to The Royal Society of Chemistry report, early cancer detection can significantly reduce cancer mortality and save lives. Great efforts are devoted to exploring new technologies for early signs of disease. For example, cancer biomarkers over a broad range of biochemical entities involving nucleic acids, proteins, sugars, and small metabolites. Such cancer biomarkers can be used for risk assessment, diagnosis, prognosis, treatment efficacy and toxicity prediction, and recurrence.

On the other hand, biomarker-based diagnosis for cancer has gained significant attention in the global market. The Fred Hutchinson Cancer Center report states that Fred Hutch researchers contribute to advancing diagnosis and screening for cancer and other diseases. For example, Fred Hutch's labs seek biomarkers for a wide range of cancers and diseases involving ovarian cancer diagnosed later. Also, researchers at the institute are identifying biomarkers that can indicate an increased risk of cancer. For example, researchers are developing a risk-prediction model combining an individual's genetic data and risk factors for determining the age at which to start colorectal cancer screening by studying biomarkers that help determine an individual's risk of prostate cancer or breast cancer, among other diseases. Such aforementioned factors support the overall market growth of the global biomarkers market during the forecast period of 2022-2028.

Market Segmentation

Within the report, the global biomarkers market is segmented into type, product, application, disease, and geography. On the basis of type, the market is segregated as safety, efficacy, validation, and Others. By Product, the market is categorized into Consumables, Services, and Software. By application, the market is segmented as diagnosis, drug discovery & development, personalized medicines, and others. By disease, the market is segregated into cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others. Geographically, the market is sub segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Based on Disease, Cancer Segment Showcases High Growth of Global Biomarkers Market

As per the Oxford Cancer Biomarkers company, approximately 28% of all resected colorectal cancer tumors are classified as Stage 2, becoming difficult to predict which patients will suffer tumor recurrence after surgery. Therefore, cancer biomarkers prove advantageous for patients suffering from end-stage cancer as they are efficient in testing for characterizing alterations in the tumor. Also, top competitive players are launching innovative programs or products for cancer patients. For instance, in April 2021, Amgen announced the launching of "Biomarker Assist," a program that helps more patients suffering from metastatic cancer non-small cell lung cancer (NSCLC) gain access to biomarker testing. Amgen's Biomarker Assist is a patient support program that demonstrates a commitment to closing the gap in testing rates. Based on biomarker status, clinicians and patients can make informed decisions on personalized treatment plans and targeted therapies that significantly improve the prognosis of many cancer patients. Such aforementioned factors are responsible for the overall market growth of the global biomarkers market during the forecast period of 2022-2028.


Recent strategic developments in global biomarkers market

The global biomarkers market has undergone several significant developments, and a few of these have been mentioned below:

  • In April 2021, F. Hoffman-La Roche Ltd. announced the launching of two cardiac biomarker tests for highly sensitive cardiac troponin T and (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These two biomarkers support cardiovascular disease management assisting clinicians in diagnosing heart attacks and managing heart failure.
  • In May 2021, QIAGEN N.V. announced the launching of the first Food and Drug Administration (FDA) approved tissue companion diagnostics, "therascreen KRAS RGQ PCR kit," for identifying KRAS G12C mutation in NSCLC tumors and expanding precision medicine options in lung cancer.


The global biomarkers market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific, Inc.; Siemens Healthineers AG; Qiagen N.V.; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Charles River Laboratories International, Inc.; Eurofins Scientific; and Enzo Biochem, Inc. are among the prominent players operating in the market.

Target audience for the report:

  • Biomarkers service providers
  • Biomarkers related associations, organizations, forums, and alliances
  • Government bodies, such as regulating authorities and policy makers
  • Venture capitalists, private equity firms, and start-up companies
  • End users of biomarkers
  • Academic and Research institutes, organizations, and consulting companies

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Type:
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Validation Biomarkers
    • Others
  • Product:
    • Consumables
    • Services
    • Software


  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Others
  • Disease:
    • Cancer
    • Cardiovascular Diseases
    • Neurological Diseases
    • Immunological Diseases
    • Others
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • Siemens Healthineers AG
    • Qiagen N.V.
    • PerkinElmer, Inc.
    • Bio-Rad Laboratories, Inc.
    • Charles River Laboratories International, Inc.
    • Eurofins Scientific
    • Enzo Biochem, Inc.

The List of Companies
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers AG
- Qiagen N.V.
- PerkinElmer, Inc.
- Bio-Rad Laboratories, Inc.
- Charles River Laboratories International, Inc.
- Eurofins Scientific
- Enzo Biochem, Inc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Purchase Options
Single User License
Site License
Enterprise License